KMT2A and cancer: And indeed, Dou and colleagues showed that peptidomimetic WINi MM-104 is active against MLLr cancer cells in vitro and works by inhibiting H3K4me2/3 at tumor-critical MLL-fusion target genes, decreasing their expression [15].